Gilead's Experimental Ulcerative Colitis Pill Beat Placebo by 23 Points on Remission, but Long-Term Safety Data Are Pending
Gilead's experimental pill emvistegrast beat placebo by 23 percentage points on ulcerative colitis remission in a Phase 2 trial, but long-term data are pending.
Medical Daily ·